Subbiah et al. [194] reported the safety and efficacy of pralsetinib in patients with RET-altered thyroid cancer from the registrational phase I/II study (ARROW) which formed the basis of approval in the USA for treatment of advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. This evidence concerns the gene RET and thyroid gland carcinoma.